NextPlat Reports Second Quarter 2025 Results

Rhea-AI Summary

NextPlat (NASDAQ: NXPL) reported Q2 2025 financial results, with revenue of $13.2 million, down from $17.0 million in Q2 2024. The company experienced a 66% reduction in net loss to $1.8 million ($0.07 per share) compared to $5.3 million in Q2 2024. Operating expenses decreased significantly to $4.7 million from $16.8 million year-over-year.

The company's Healthcare Operations faced challenges with decreased pharmacy prescription revenue and 340B contract revenue, while e-Commerce Operations showed growth in connectivity products and services. Gross profit margin declined to 21.8% from 34.5% year-over-year. The company ended Q2 with $16.6 million in cash and expects annual expense savings of over $1.0 million from operational improvements.

Positive

• Net loss decreased 66% year-over-year to $1.8 million
• Significant reduction in operating expenses from $16.8M to $4.7M
• Strong cash position of $16.6 million
• Expected annual expense savings of over $1.0 million
• Record-levels of recurring airtime contracts in e-Commerce segment
• Successful expansion of OPKO healthcare products on Alibaba's Tmall Global

Negative

• Revenue declined 22.4% to $13.2M from $17.0M year-over-year
• Gross profit margin decreased to 21.8% from 34.5%
• Healthcare Operations revenue dropped due to decreased pharmacy prescriptions
• 340B contract revenue decreased by $2.0M to $1.0M
• E-Commerce gross margin declined to 25.9% from 31.6%

Insights

Financial Analyst

NextPlat's Q2 shows revenue decline to $13.2M but significant cost-cutting progress, reduced losses despite healthcare segment challenges.

NextPlat's Q2 2025 results reveal a company in transition, with consolidated revenue declining to $13.2 million from $17.0 million in Q2 2024. This 22% revenue drop stems primarily from challenges in the Healthcare Operations segment, where pharmacy prescription revenue fell by $2.3 million and 340B contract revenue decreased by $2.0 million.

The gross profit margin contracted significantly to 21.8% from 34.5% year-over-year, with Healthcare Operations' margins declining to 19.9% from 35.2%. This compression reflects both lower prescription volume and the industry-wide challenge of drug price increases outpacing reimbursement adjustments. E-Commerce margins also decreased to 25.9% from 31.6% due to new airtime costs and temporary rate reductions.

On a positive note, operating expenses decreased substantially to $4.7 million from $16.8 million in Q2 2024, though this comparison is skewed by $9.7 million in non-recurring expenses in the prior year. More importantly, management has implemented operational efficiencies and staff adjustments expected to yield annual savings exceeding $1.0 million, some of which will be reinvested to drive growth.

The net loss attributable to shareholders improved by 66% to $1.8 million ($0.07 per diluted share) compared to $5.3 million ($0.28 per diluted share) in Q2 2024. The company maintains a solid cash position of $16.6 million.

NextPlat's e-Commerce segment showed strength with growing connectivity product sales and record levels of recurring airtime contracts. The company is also expanding its product offerings, including OPKO healthcare products in China and launching Florida Sunshine products in the UK and EU markets. Management has outlined three strategic objectives: continued operational efficiency improvements, talent optimization, and prudent investment in growth opportunities.

The financials reflect a company actively restructuring to improve profitability while facing significant headwinds in its largest revenue segment. The substantial cash position provides runway for the transformation, but investors should monitor whether the cost-cutting measures and new growth initiatives can offset the revenue and margin pressures in the Healthcare segment.

Company Reports $13.2M in Q2 Revenue, Achieves Significant Reduction in Operating Expenses and Continues Cost Reduction and Efficiency Improvements to Support Growth

COCONUT GROVE, Fla., Aug. 14, 2025 /PRNewswire/ -- NextPlat Corp (NASDAQ: NXPL, NXPLW) ("NextPlat" or the "Company"), a global consumer products and services company providing healthcare and technology solutions through eCommerce and retail channels worldwide, today announced the financial results for the quarter-ended June 30, 2025, reflecting the performance of its e-Commerce and Healthcare Operations.

"Results for the second quarter reflect continued top-line trends in the business, highlighted by strong e-Commerce growth and challenges in our Healthcare Operations as we continue to implement activities across the business to improve our operations, benefits that we believe are just beginning to be demonstrated by a reduced cost structure," said David Phipps, Interim CEO, President and CEO of Global Operations at NextPlat Corp. "Since the close of the second quarter, NextPlat continued to make progress against its plans to maximize the value of its business and adapt to the domestic and international challenges which have impacted us over the past few months. Our teams have been working hard to implement a broad array of initiatives within our Healthcare Operations which we believe have the potential to positively transform our business while enabling us to better attract and retain our customers. We are especially excited about the business expansion opportunities we see in the near-term and the new relationships we are working to form which will support our efforts to move into higher margin and higher growth segments of the Healthcare spectrum," said Mr. Phipps.

Second Quarter 2025 Financial Highlights:

• Consolidated revenue for the quarter ended June 30, 2025, was approximately $13.2 million compared to approximately $17.0 million for the quarter ended June 30, 2024. The decrease in consolidated revenue was primarily driven by a decline in Healthcare Operations due to the following:
  • A $2.3 million decrease in pharmacy prescription and other revenue, net of PBM fees, to approximately $8.2 million for the quarter ended June 30, 2025 when compared to approximately $10.5 million in the prior year quarter, resulted from the decrease in pharmacy prescriptions filled which was influenced in part by the continued changes in provider relationships and shifts in patient flow due to insurance network adjustments or provider decisions to align with different pharmacy partners.
  • A $2.0 million decrease in pharmacy 340B contract revenue to approximately $1.0 million for the quarter ended June 30, 2025 when compared to approximately $3.0 million in the prior year quarter, resulted from certain relationships transitioning to other pharmacy partners, some covered entities opened in-house pharmacies, and another covered entity no longer participates in the 340B program.
     
• Overall gross profit margin for the quarter ended June 30, 2025, declined to approximately 21.8% from 34.5% when compared to the prior year quarter. Gross profit margin from our Healthcare segment decreased to approximately 19.9% in the second quarter of 2025 from 35.2% in the second quarter of 2024 and was primarily attributable to the decrease in pharmacy prescriptions filled and 340B revenue as well as the continued industry-wide impact of drug price increases outpacing reimbursement rate adjustments. Gross profit margin for e-Commerce Operations decreased to approximately 25.9% from 31.6% when compared to the prior year quarter primarily due to a service provider airtime contract that expired on December 31, 2024, which introduced new airtime costs beginning January 1, 2025, and temporary rate reductions for some customers continuing to be affected by ongoing network service interruptions.
   
• Operating expenses for the quarter ended June 30, 2025, decreased to approximately $4.7 million compared to approximately $16.8 million in the prior year quarter which included approximately $9.7 million in non-recurring expenses such as an impairment loss from the write-down of certain long-lived assets. As expected, overall operational costs decreased due to a decrease in stock-based compensation for grants fully vested a reduction in executive compensation, and ongoing headcount reductions. The Company has undertaken a series of proactive steps designed to improve its expense structure. As a result of ongoing operational process efficiency improvements, staff adjustments and other cost reduction efforts, the Company anticipates annual expense savings in excess of approximately $1.0 million, a portion of which management intends to reinvest into the business to support the launch of new and expanded service offerings and drive revenue growth.
   
• Net loss attributable to NextPlat Corp common shareholders for the quarter ended June 30, 2025, decreased 66% to approximately $1.8 million, or ($0.07) per diluted share, compared to a net loss of approximately $5.3 million, or ($0.28) diluted earnings per share reported for the quarter ending June 30, 2024.
   
• The Company ended the quarter with approximately $16.6 million in cash.

Organizational Highlights and Recent Business Developments:

• During the second quarter, the Company continued its ongoing efforts to implement cost-reduction and business process improvements in its Healthcare Operations such as technology upgrades, and the recruitment of dedicated sales professionals focused on opportunities in the 340B and Long-Term Care segment. The positive impact of these efforts is expected to contribute to operational results throughout the remainder of 2025 and into 2026.
   
• Following the passing of our former CEO and Chairman, Charles M. Fernandez, and as outlined in the Interim CEO Shareholder Update Letter dated June 30, 2025, the Company completed an extensive review of the business with a particular focus on its Healthcare Operations, which currently represents the largest component of revenue. As a result, the Company has identified three primary objectives: continued operational process efficiency and cost reduction efforts to drive maximum ROI; ensuring that the necessary talent is leading the business and that they are empowered to manage and drive growth; and, renewing a commitment to prudently invest in the business to help capitalize on opportunities, both organic and non-organic, while enhancing cashflow and long-term profitability. The Company expects to announce significant developments against each of these objectives over the course of the next 60 days.
   
• In the second quarter, e-Commerce revenue for its connectivity products and services continues to grow, driven by record-levels of recurring airtime contracts and elevated hardware sales. The Company continues to see near-term growth opportunities in this business segment as it secures new connectivity contracts and expands its mission-critical communications capabilities for enterprise, government, and humanitarian organizations across Europe. Its global reach and increased focus on higher margin airtime services drove recurring airtime revenue and billable customers to record levels.
   
• Growth in the Company's sales of OPKO Healthcare ("OPKO")-branded human health and wellness products on Alibaba Group Holding Limited's ("Alibaba") Tmall Global in China continues despite limited permissible inventory levels. The Company is working to secure increased inventory volumes to meet demand while it awaits regulatory approval to introduce OPKO pet health products as interest remains high. Approval of the sale of OPKO pet health products is still expected during the fourth quarter with sales to commence approximately 12 weeks after receipt. All current OPKO products are not subject to any tariffs as they are not produced in the United States.
   
• As disclosed on April 11, 2025, the Company is strategically adjusting its e-Commerce development program in light of evolving trade conditions between the United States and China. While the planned launch of our Florida Sunshine-branded line of US-produced vitamins and related products in China is temporarily on hold, we are pleased to announce that Florida Sunshine products are now launching in the UK and EU. We remain committed to bringing these products to the Chinese market when conditions are more favorable.

Second Quarter 2025 Conference Call Notification
NextPlat's Interim CEO, President and CEO of Global Operations, David Phipps, and Chief Financial Officer, Cecile Munnik, will host a conference call at 8:30 a.m. Eastern today to discuss the results for the second quarter ended June 30, 2025, and recent developments.

To access the call, please use the following information:

Date:	Thursday, August 14, 2025
Time:	8:30 a.m. Eastern time
Toll-free dial-in number:	1-800-836-8184
International dial-in number:	1-646-357-8785
Conference webcast link:	https://app.webinar.net/okKXG80G0MA

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization.

The conference call will be broadcast live and available for replay at https://app.webinar.net/okKXG80G0MA and via the investor relations section of the Company's website at https://ir.nextplat.com/news-events/ir-calendar. A replay of the conference call will be available after 12:00 p.m. Eastern time through August 21, 2025.

Toll-free replay number:	1-888-660-6345
International replay number:	1-646-517-4150
Replay entry code:	34889#

The financial information included in this press release should be read in conjunction with the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 filed with the Securities and Exchange Commission.

About NextPlat Corp
Nextplat is a global consumer products and services company providing healthcare and technology solutions through e-Commerce and retail channels worldwide. Through acquisitions, joint ventures and collaborations, the Company seeks to assist businesses in selling their goods online, domestically, and internationally, allowing customers and partners to optimize their e-Commerce presence and revenue. NextPlat currently operates an e-Commerce communications division offering voice, data, tracking, and IoT products and services worldwide as well as pharmacy and healthcare data management services in the United States through its subsidiary, Progressive Care.

Forward-Looking Statements
Certain statements in this release constitute forward-looking statements. These statements include the capabilities and success of the Company's business and any of its products, services or solutions. The words "believe," "forecast," "project," "intend," "expect," "plan," "should," "would," and similar expressions and all statements, which are not historical facts, are intended to identify forward-looking statements. These forward-looking statements involve and are subject to known and unknown risks, uncertainties and other factors, including the Company's ability to launch additional e-commerce capabilities for consumer and healthcare products and its ability to grow and expand as intended, any of which could cause the Company to not achieve some or all of its goals or the Company's previously reported actual results, performance (finance or operating), including those expressed or implied by such forward-looking statements. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), copies of which may be obtained from the SEC's website at www.sec.gov. The Company assumes no, and hereby disclaims any, obligation to update the forward-looking statements contained in this press release.

Media and Investor Contact for NextPlat Corp:

Michael Glickman
MWGCO, Inc.
917-397-2272
mike@mwgco.net 

NEXTPLAT CORP AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (In thousands, except per share data) (Unaudited)
		Three Months Ended June 30,								Six Months Ended June 30,
		2025				2024				2025				2024
Sales of products, net		$	12,263			$	14,030			$	25,345			$	28,150
Revenues from services			977				2,959				2,420				6,332
Revenue, net			13,240				16,989				27,765				34,482
Cost of products			10,346				11,120				21,398				23,741
Cost of services			11				11				21				21
Cost of revenue			10,357				11,131				21,419				23,762
Gross profit			2,883				5,858				6,346				10,720
Operating expenses:
Selling, general and administrative			1,473				1,603				2,905				2,919
Salaries, wages and payroll taxes			2,549				3,452				5,264				6,815
Impairment loss			—				9,792				—				9,924
Professional fees			515				1,004				1,120				1,989
Depreciation and amortization			150				203				320				412
Intangible asset amortization			25				700				51				1,398
Total operating expenses			4,712				16,754				9,660				23,457
Loss before other (income) expense			(1,829)				(10,896)				(3,314)				(12,737)
Other (income) expense:
Loss (gain) on sale or disposal of property and equipment			163				—				163				(1)
Interest expense			15				19				33				41
Interest earned			(99)				(197)				(207)				(412)
Foreign currency exchange rate variance			(150)				5				(211)				31
Total other (income) expense			(71)				(173)				(222)				(341)
Loss before income taxes and non-controlling interest			(1,758)				(10,723)				(3,092)				(12,396)
Income taxes			(31)				(20)				(40)				(47)
Net loss			(1,789)				(10,743)				(3,132)				(12,443)
Net loss attributable to non-controlling interest			—				5,432				—				5,652
Net loss attributable to NextPlat Corp		$	(1,789)			$	(5,311)			$	(3,132)			$	(6,791)
Comprehensive loss:
Net loss		$	(1,789)			$	(10,743)			$	(3,132)			$	(12,443)
Foreign currency loss			(58)				(27)				(69)				(9)
Comprehensive loss		$	(1,847)			$	(10,770)			$	(3,201)			$	(12,452)
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS		$	(1,789)			$	(5,311)			$	(3,132)			$	(6,791)
Weighted number of common shares outstanding – basic and diluted			25,963				18,824				25,963				18,774
Basic and diluted loss per share		$	(0.07)			$	(0.28)			$	(0.12)			$	(0.36)

 

NEXTPLAT CORP AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except number of shares and par value) (Unaudited)
		June 30, 2025				December 31, 2024
		(Unaudited)				(Audited)
ASSETS
Current Assets
Cash		$	16,635			$	19,960
Accounts receivable, net			3,153				4,895
Receivables - other, net			854				732
Inventory, net			5,215				4,881
Unbilled revenue			313				237
VAT receivable			371				371
Prepaid expenses			314				404
Total Current Assets			26,855				31,480
Property and equipment, net			2,839				3,407
Goodwill			156				156
Intangible assets, net			473				524
Operating right-of-use assets, net			623				812
Finance right-of-use assets, net			—				5
Deposits			87				94
Total Other Assets			1,339				1,591
Total Assets		$	31,033			$	36,478
LIABILITIES AND EQUITY
Current Liabilities
Accounts payable and accrued expenses		$	5,213			$	7,230
Contract liabilities			303				89
Notes payable			213				380
Due to related party			1				48
Operating lease liabilities			378				404
Finance lease liabilities			—				5
Income taxes payable			100				54
Total Current Liabilities			6,208				8,210
Long Term Liabilities:
Notes payable, net of current portion			943				1,032
Operating lease liabilities, net of current portion			274				438
Total Liabilities			7,425				9,680
Commitments and Contingencies			—				—
Equity
Common stock ($0.0001 par value; 50,000,000 shares authorized, 25,963,051 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively)			3				3
Additional paid-in capital			75,708				75,697
Accumulated deficit			(52,082)				(48,950)
Accumulated other comprehensive loss			(135)				(66)
Equity attributable to NextPlat Corp stockholders			23,494				26,684
Equity attributable to non-controlling interests			114				114
Total Equity			23,608				26,798
Total Liabilities and Equity		$	31,033			$	36,478

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/nextplat-reports-second-quarter-2025-results-302529484.html

SOURCE NextPlat Corp.

FAQ

What were NextPlat's (NXPL) Q2 2025 earnings results?

NextPlat reported Q2 2025 revenue of $13.2 million, a net loss of $1.8 million ($0.07 per share), and ended the quarter with $16.6 million in cash.

How much did NextPlat's operating expenses decrease in Q2 2025?

NextPlat's operating expenses decreased to $4.7 million from $16.8 million in the prior year quarter, including reductions in stock-based compensation and executive compensation.

What caused the decline in NextPlat's Healthcare Operations revenue?

The decline was due to a $2.3 million decrease in pharmacy prescription revenue and a $2.0 million decrease in 340B contract revenue, caused by changes in provider relationships and shifts in patient flow.

What is NextPlat's strategy for future growth?

NextPlat is focusing on three objectives: operational efficiency and cost reduction, strengthening leadership talent, and prudent business investment in both organic and non-organic opportunities to enhance cashflow and profitability.

How is NextPlat's e-Commerce business performing?

The e-Commerce segment is showing growth with record-levels of recurring airtime contracts and elevated hardware sales, particularly in connectivity products and services across Europe.